About Synklino
Synklino is a company based in Copenhagen (Denmark) founded in 2017 by Mads Gravers Jeppesen and Thomas Nitschke Kledal.. Synklino has raised $32.25 million across 5 funding rounds from investors including PKA, Eir Ventures and Danmarks Eksport- og Investeringsfond. The company has 8 employees as of November 30, 2024. Synklino offers products and services including SYN002. Synklino operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, CareDx, Generate Biomedicines and HOOKIPA Pharma, among others.
- Headquarter Copenhagen, Denmark
- Employees 8 as on 30 Nov, 2024
- Founders Mads Gravers Jeppesen, Thomas Nitschke Kledal
- Stage Minicorn
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Synklino Aps
-
Annual Revenue
-
Net Profit
$-1.52 K (USD)80as on Dec 31, 2022
-
EBITDA
-
Total Equity Funding
$32.25 M (USD)
in 5 rounds
-
Latest Funding Round
$31.9 M (USD), Series A
Jun 08, 2022
-
Investors
PKA
& 2 more
-
Employee Count
8
as on Nov 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Synklino
Synklino offers a comprehensive portfolio of products and services, including SYN002. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Eliminates CMV risk in transplant recipients via ex vivo or in vivo treatment.
Unlock access to complete
Unlock access to complete
Funding Insights of Synklino
Synklino has successfully raised a total of $32.25M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $31.9 million completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $31.9M
-
First Round
First Round
(13 Jul 2018)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Series A - Synklino | Valuation | PKA | |
| Nov, 2021 | Amount | Seed - Synklino | Valuation |
investors |
|
| Sep, 2020 | Amount | Seed - Synklino | Valuation | Eir Ventures , Vaekstfonden |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Synklino
Synklino has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include PKA, Eir Ventures and Danmarks Eksport- og Investeringsfond. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is provided for innovative medical developments.
|
Founded Year | Domain | Location | |
|
Provision of financing, loans, equity, and insurance for Danish export and investment activities.
|
Founded Year | Domain | Location | |
|
Serves as a pension fund providing benefits for employees.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Synklino
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Synklino
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Synklino Comparisons
Competitors of Synklino
Synklino operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, CareDx, Generate Biomedicines and HOOKIPA Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Medical solutions for transplant patients are developed and provided.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Synklino
Frequently Asked Questions about Synklino
When was Synklino founded?
Synklino was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Synklino located?
Synklino is headquartered in Copenhagen, Denmark.
Who is the current CEO of Synklino?
Thomas Nitschke Kledal is the current CEO of Synklino. They have also founded this company.
Is Synklino a funded company?
Synklino is a funded company, having raised a total of $32.25M across 5 funding rounds to date.
How many employees does Synklino have?
As of Nov 30, 2024, the latest employee count at Synklino is 8.
What does Synklino do?
Synklino was founded in 2017 in Copenhagen, Denmark, within the biotechnology sector. Focus is placed on developing therapeutic drugs for chronic viral infections. The lead product candidate, SYN002, is an immunotoxin designed to target the US28 receptor for Cytomegalovirus (CMV) treatment. Operations center on advancing these antiviral therapies through research and clinical development stages. Co-founders include Mads Gravers Jeppesen and Thomas Nitschke Kledal, with the latter serving as CEO.
Who are the top competitors of Synklino?
Synklino's top competitors include Moderna, CareDx and Adaptive Biotechnologies.
What products or services does Synklino offer?
Synklino offers SYN002.
Who are Synklino's investors?
Synklino has 3 investors. Key investors include PKA, Eir Ventures, and Danmarks Eksport- og Investeringsfond.
What is Synklino's valuation?
The valuation of Synklino is $4.4M as of Nov 2021.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.